sovaprevir

{{Short description|Chemical compound}}

{{Infobox drug

| drug_name =

| IUPAC_name = (4R)-N-{(1R,2S)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-1-{(2S)-3,3-dimethyl-2-[2-oxo-2-(1-piperidinyl)ethyl]butanoyl}-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolinamide

| image = Sovaprevir.svg

| alt =

| caption =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| onset =

| elimination_half-life =

| excretion =

| CAS_number = 1001667-23-7

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| PubChem = 53362096

| ChemSpiderID = 28529313

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 2ND9V3MN6O

| DrugBank =

| KEGG = D10166

| ChEMBL = 2105750

| NIAID_ChemDB = 491583

| synonyms = ACH-1625

| chemical_formula =

| C=43 | H=53 | N=5 | O=8 | S=1

| SMILES = CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7

| StdInChI = 1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1

| StdInChIKey = MHFMTUBUVQZIRE-WINRQGAFSA-N

}}

Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.{{cite journal | vauthors = De Clercq E | title = Current race in the development of DAAs (direct-acting antivirals) against HCV | journal = Biochemical Pharmacology | volume = 89 | issue = 4 | pages = 441–52 | date = June 2014 | pmid = 24735613 | doi = 10.1016/j.bcp.2014.04.005 }} Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012.{{cite web | url = http://www.achillion.com/sovaprevir_ACH1625 | title = Sovaprevir HCV NS3/4A Protease Inhibitor | publisher = Achillion }}